New hope for pancreatic cancer patients in major trial
NCT ID NCT07238283
Summary
This large Phase 3 trial is comparing a new combination of cancer drugs against the current standard treatment for advanced pancreatic cancer that has spread. The main goal is to see if the new treatment helps patients live longer. Researchers will enroll 662 adults with newly diagnosed metastatic pancreatic cancer who haven't had previous treatment for their spread disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.